Core Viewpoint - Cybin Inc. (CYBN) shows significant upside potential based on Wall Street analysts' short-term price targets, with a mean target of $78.8 indicating an 831.4% upside from the current price of $8.46 [1][2]. Price Targets and Estimates - The average price target consists of five estimates ranging from a low of $25.00 to a high of $150.00, with a standard deviation of $52.91, indicating variability among analysts [2]. - The lowest estimate suggests a 195.5% increase, while the highest points to a 1673.1% upside [2]. - A low standard deviation indicates a strong agreement among analysts regarding the price movement direction [9]. Analyst Sentiment and Earnings Estimates - Analysts exhibit strong agreement in revising CYBN's earnings estimates higher, which correlates with potential stock price increases [4][11]. - The Zacks Consensus Estimate for the current year has risen by 3.1% over the past month, with two estimates increasing and no negative revisions [12]. - CYBN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, and reliance solely on them may not yield favorable returns [3][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

GeneDx Holdings Corp. (WGS) closed the last trading session at $80.47, gaining 24.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $101.53 indicates a 26.2% upside potential.The average comprises eight short-term price targets ranging from a low of $78.00 to a high of $115.00, with a standard deviation of $14.73. While the lowest estimate indicates a decline of 3.1% from the curr ...

Group 1 - VNET Group's shares have increased by 62.9% in the past four weeks, closing at $9.04, with a mean price target of $13.7 indicating a potential upside of 51.6% [1][2] - The mean estimate consists of seven short-term price targets with a standard deviation of $3.3, suggesting variability in analyst predictions; the lowest estimate is $10.00 (10.6% increase), while the highest is $20.00 (121.2% increase) [2][9] - Analysts show strong agreement on VNET's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for VNET has increased by 18.2% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - VNET holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Group 1 - Marex Group PLC (MRX) closed at $39.49, with a mean price target of $51.56 indicating a 30.6% upside potential [1] - The mean estimate consists of nine short-term price targets with a standard deviation of $6.62, ranging from a low of $36.00 (8.8% decline) to a high of $58.00 (46.9% increase) [2] - Analysts show strong agreement on MRX's ability to report better earnings, which supports the potential for stock upside [4][11] Group 2 - Recent revisions in earnings estimates have been positive, with one estimate increasing and no negative revisions, leading to a 1% increase in the Zacks Consensus Estimate [12] - MRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be entirely reliable, it suggests a positive direction for MRX's price movement [14]

Group 1 - GH Research PLC (GHRS) closed at $15.99, with a 33.4% gain over the past four weeks, and a mean price target of $33.14 suggests a 107.3% upside potential [1] - The average price targets from analysts range from a low of $25.00 to a high of $40.00, indicating a potential increase of 56.4% to 150.2% from the current price level, with a standard deviation of $5.34 reflecting the variability of estimates [2] - Analysts show strong agreement on GHRS's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for GHRS's current year earnings has increased by 0.8% over the last 30 days, with one estimate moving higher and no negative revisions [12] - GHRS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Rapt Therapeutics (RAPT) shares have increased by 5.8% recently, closing at $8.72, with a mean price target of $24.75 suggesting a potential upside of 183.8% [1][2] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $17.35, indicating variability among analysts [2] - The lowest estimate is $8.00, suggesting an 8.3% decline, while the highest estimate is $48.00, indicating a potential surge of 450.5% [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about RAPT's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 24.1%, with one estimate moving higher and no negative revisions [12] - RAPT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][10] - Price targets can often be inflated due to business incentives, leading to overly optimistic projections [8]

Group 1 - LENZ Therapeutics, Inc. (LENZ) shares have increased by 17% over the past four weeks, closing at $33.73, with a mean price target of $44.14 indicating a potential upside of 30.9% [1] - The average price targets from analysts range from a low of $36.00 to a high of $60.00, with a standard deviation of $8.63, suggesting variability in estimates [2] - Analysts show a consensus that LENZ will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for LENZ's current year earnings has increased by 1.5% over the last 30 days, with one estimate moving higher and no negative revisions [12] - LENZ holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it does suggest a positive direction for price movement [14]

Group 1 - Navigator Holdings (NVGS) closed at $15.45, with a 7.7% gain over the past four weeks, and a mean price target of $21.75 suggests a 40.8% upside potential [1] - The mean estimate includes four short-term price targets with a standard deviation of $2.63, indicating variability among analysts; the lowest estimate is $18.00 (16.5% increase), while the highest is $24.00 (55.3% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 4.9% over the last 30 days, with one estimate moving higher and no negative revisions [12] - NVGS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it does suggest a positive direction for price movement [14]

Core Viewpoint - Alkermes (ALKS) shows potential for significant upside, with a mean price target of $40.33 indicating a 33.2% increase from the current price of $30.28 [1] Price Targets and Estimates - The mean estimate consists of 15 short-term price targets with a standard deviation of $6.84, indicating variability among analysts [2] - The lowest estimate is $27.00, suggesting a 10.8% decline, while the highest estimate is $52.00, indicating a potential surge of 71.7% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates - Analysts have shown increasing optimism about Alkermes' earnings prospects, with a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 1% over the past month, with one estimate rising and no negative revisions [12] - Alkermes holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets can provide some guidance, they should be approached with skepticism, as they may not accurately reflect future stock movements [10]

Core Viewpoint - Montrose Environmental (MEG) has shown a slight increase in share price, but analysts suggest there is significant upside potential based on price targets and earnings estimates [1][11]. Price Targets - The mean price target for MEG is $28.83, indicating a potential upside of 25.4% from the current price of $22.99 [1]. - Price targets from analysts range from a low of $18.00 to a high of $35.00, with a standard deviation of $6.55, reflecting variability in estimates [2]. - The lowest estimate suggests a decline of 21.7%, while the highest indicates a potential upside of 52.2% [2]. Analyst Consensus and Earnings Estimates - Analysts have shown increasing optimism regarding MEG's earnings prospects, with a strong agreement in revising EPS estimates higher [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 4.7%, with one estimate moving higher and no negative revisions [12]. - MEG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10]. - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8]. - A low standard deviation among price targets indicates a high degree of agreement among analysts, which can be a starting point for further research [9].